Investors and Advisors, and Life Sciences Analysts are Invited to Attend the New York City Event; Virtual Webcast Link ...
Advancing U.S.-based cGMP manufacturing to support clinical and future commercial objectives of a novel siRNA therapy ...
A Critical Next Step in Advancing Phio’s PH-762 Program to Treat Cutaneous Carcinomas Phio Pharmaceuticals Corp.
The tumor begins before birth. Somewhere in the developing fetus, neural crest cells that should have matured into adrenal tissue or sympathetic ganglia take a wrong turn, and a child is born ...
Neuroblastoma kills more children under one year of age than any other extracranial solid tumor, and high-risk cases have ...
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary ...
This study provides valuable insights into the role of MATR3 in oocyte maturation and folliculogenesis, using conditional knockout mice and in vitro follicle culture systems to show that MATR3 is ...
Discusses Preliminary Phase I/II Data for SRP-1001 in FSHD1 and SRP-1003 in DM1 March 25, 2026 8:30 AM EDT Anupam Rama - JPMorgan Chase & Co, Research Division Konstantinos Biliouris - Oppenheimer & ...
The FDA has granted Fast Track designation to BW-20805, an investigational small interfering RNA therapy for hereditary angioedema.
Phase 1 data suggest that WVE-007, an investigational siRNA drug given by injection, leads to reductions in visceral fat, waist circumference, and body weight.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results